Elanco Corp (ELAN) - Price-to-Projected Revenue Ratio

Elanco - graphic logo of issuer ELAN

The forward P/S trend reflects a dynamic where 2.60 determines the latest valuation metric for Elanco Animal Health (ELAN). Strict FDA oversight and capital-intensive R&D are capping growth, while pet innovations and debt reduction are generating positive momentum. The implementation of robotics in drug packaging is driving cost optimization, which adjusts the trajectory of market expectations regarding the future revenues of Elanco Animal Health (ELAN).

Elanco - ELAN Market Cap to Future Revenue Ratio (period 07/04/2022 - 11/13/2026)

ELAN (Elanco Corp): analytical breakdowns and indicator data

- stock price and consensus target price:
Stock Quotes Elanco|ELAN - Fair Value Consensus
- market capitalization indicators:
Market Value Elanco Corp|ELAN - Value Adjusted for Debt and Cash
- book value of equity indicators:
Book Value per Share Elanco|ELAN - Total Stockholders' Equity|Market Value to Book Value Ratio elanco.com|ELAN - Company Total Asset Base
- debt and solvency information:
Debt to Equity Elanco Animal Health|ELAN - Long-Term Liabilities to Capital|Short-Term Debt to Equity Ratio Elanco Animal Health|ELAN - Company Aggregate Debts|Debt to Book Capitalization Ratio Elanco Corp|ELAN - Company Long-Term Loans and Borrowings|Company Short-Term Debts Elanco|Quick Ratio elanco.com
- financial results and valuation multiples details:
ELAN - Company Net Income|Expected Profit Elanco Animal Health|ELAN - Business Payback Period|Forward P/E Multiple Elanco Animal Health Inc.|ELAN - Price to Earnings Adjusted for Growth Rate|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Elanco Corp|ELAN - Profit before payment of interest, taxes and amortization|Net earnings per share (EPS TTM) Elanco|ELAN - Net earnings per share (EPS TTM)|Year-over-year earnings per share growth for the last twelve months elanco.com|ELAN - Earnings per share growth this year|Earnings growth forecast for next year Elanco Animal Health
- revenue and sales details:
ELAN - Company Sales|Company Projected Revenue Elanco|ELAN - Price to Sales|Forward Price-to-Revenue Multiple Elanco Corp
Fundamental company analysis:ELAN (Elanco)
Original product of elanco.com

The forward P/S ratio determines the market value of an asset by discounting future revenue streams, allowing investors to filter out short-term noise from long-term liquidity trends. By analyzing the forward P/S of an issuer on the GURU.Markets platform, an investor assesses the efficiency of monetizing future sales. For Elanco Animal Health (ELAN), this metric reflects market confidence in the commercialization of innovative veterinary drugs and sustainable responsible farming technologies.

Key competitors

Corteva - Forward Price-to-Revenue Multiple|Forward Price to Sales NTR|CF - Price-to-Projected Revenue Ratio|Forward Price to Sales MOS (Mosaic Co.)|BCPC: Forward P/S Multiple|Market Cap to Future Revenue Ratio FMC Corp (FMC)|Price-to-Projected Revenue Ratio The Scotts Miracle-Gro Company|Phibro Animal Health Corp (PAHC) - Market Cap to Expected Sales Ratio|Price-to-Projected Revenue Ratio CVR Partners Corp (UAN)|ODC - Market Cap to Future Revenue Ratio|Intrepid Potash, Inc. - Forward Price-to-Revenue Multiple|Forward P/S Multiple lavoroagro.com LVRO|AVD - Price-to-Projected Revenue Ratio|Forward Price to Sales GRO (Brazil Potash Corp)|ICCC: Forward P/S Multiple|Forward Price-to-Revenue Multiple Enlightify Corporation|SEED (Origin Agritech Ltd.) - Forward P/S Multiple|Market Cap to Future Revenue Ratio cgagri.com CGA|Price-to-Projected Revenue Ratio S&W Seed Co. (SANW)